Federated Hermes, Inc. Sigilon Therapeutics, Inc. Transaction History

Federated Hermes, Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 08, 2023	SELL	$0.34 - $1.38 $523 - $2,125	-1,540 Reduced 54.67%	1,277 $1,000
Q4 2022 Feb 13, 2023	SELL	$0.29 - $0.69 $423 - $1,006	-1,459 Reduced 34.12%	2,817 $0
Q3 2022 Nov 14, 2022	SELL	$0.48 - $0.86 $186 - $334	-389 Reduced 8.34%	4,276 $2,000
Q2 2022 Aug 15, 2022	BUY	$0.74 - $1.64 $645 - $1,430	872 Added 22.99%	4,665 $4,000
Q1 2022 May 13, 2022	BUY	$1.24 - $3.03 $2,384 - $5,826	1,923 Added 102.83%	3,793 $6,000
Q4 2021 Feb 14, 2022	BUY	$2.58 - $6.13 $4,824 - $11,463	1,870 New	1,870 $5,000

Ticker SGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,399,300
Description
Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neuro...

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

Stay updated on Federated Hermes, Inc. with notifications on news.